Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenzhen Fan

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Therapeutic Advances in Gastroenterology|March 16, 2026
Discrepancies between patients' and gastroenterologists' perceptions of diagnosis and treatment in ulcerative colitis: a multicenter retrospective studyZhenzhen Fan, Ruixia Li, Xin Liu, et al.
Nature Communications|April 12, 2019
Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibitionLei Gao, Yong Hu, Yahui Tian, et al.
Cancer Research|December 13, 2022
PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung CancerLi-Li Long, Si-Cong Ma, Ze-Qin Guo, et al.
EMBO Molecular Medicine|November 30, 2021
A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLCYue Lu, Zhenzhen Fan, Su-Jie Zhu, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Therapeutic Advances in Gastroenterology|March 16, 2026
Discrepancies between patients' and gastroenterologists' perceptions of diagnosis and treatment in ulcerative colitis: a multicenter retrospective studyZhenzhen Fan, Ruixia Li, Xin Liu, et al.
Nature Communications|April 12, 2019
Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibitionLei Gao, Yong Hu, Yahui Tian, et al.
Cancer Research|December 13, 2022
PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung CancerLi-Li Long, Si-Cong Ma, Ze-Qin Guo, et al.
EMBO Molecular Medicine|November 30, 2021
A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLCYue Lu, Zhenzhen Fan, Su-Jie Zhu, et al.
Pageof 7